And Then There Was Mills - Mother Jones
At the start of last week, there were four members of Congress at risk of expulsion due to allegations of severe misconduct. Two of those members, Reps. Tony Gonzales (R-Texas) and Eric Swalwell (...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott ... - The Bakersfield Californian
NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Abbott and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On February 17, 2022, the U.S. Food and Drug Administration (“FDA”) announced its investigation into four consumer complaints of infant illness related to powdered infant formula produced by Abbott in its Sturgis, Michigan facility. Among other things, the FDA indicated that it had already found several positive contamination results from onsite environmental samples for a bacteria linked to infant illnesses and death. The same day, Abbott recalled certain popular infant formula products manufactured in the Sturgis facility.
On this news, Abbott’s stock price fell $3.79 per share, or 3.14%, to close at $116.79 per share on February 18, 2022.
On March 22, 2022, the FDA reported its findings that, among other things, Abbott had failed to establish adequate process controls for its infant formula related to the presence of microorganisms and to prevent environmental contamination.
On this news, Abbott’s stock price fell $4.97 per share, or 4%, to close at $116.92 per share on March 23, 2022.
On April 22, 2022, a redacted copy of a whistleblower...
Read Full Story: https://news.google.com/__i/rss/rd/articles/CBMirwFodHRwczovL3d3dy5iYWtlcnNma...